Return-path: <bounce-18416124_HTML-982008319-36209518-10831468-447@bounce.broadcastemail.asco.org>
Envelope-to: info@seeinindia.com
Delivery-date: Mon, 15 Jun 2015 19:13:06 +0000
Received: from mta.broadcastemail.asco.org ([64.132.92.206]:53511)
	by bh-in-11.webhostbox.net with esmtp (Exim 4.85)
	(envelope-from <bounce-18416124_HTML-982008319-36209518-10831468-447@bounce.broadcastemail.asco.org>)
	id 1Z4Zof-00299J-5c
	for info@seeinindia.com; Mon, 15 Jun 2015 19:13:06 +0000
Received: by mta.broadcastemail.asco.org id hfshs2163hs4 for <info@seeinindia.com>; Mon, 15 Jun 2015 13:13:01 -0600 (envelope-from <bounce-18416124_HTML-982008319-36209518-10831468-447@bounce.broadcastemail.asco.org>)
From: "Daily News" <dailynews@asco.org>
To: <info@seeinindia.com>
Subject: 2015 ASCO Annual Meeting Recap: A Look at Precision Medicine Trials, Cost of Cancer Care, and Plenary Presentations
Date: Mon, 15 Jun 2015 13:13:01 -0600
List-Unsubscribe: <mailto:leave-fc5015787165027c77101f2d205921-fe271d7877640475761579-fe5d177677640d78741c-fe6015707d670579731c-ff60107472@leave.broadcastemail.asco.org>
MIME-Version: 1.0
x-job: 10831468_36209518
Message-ID: <b9dbf12e-04e0-4732-a1bd-8c260ead43d1@xtinmta4100.xt.local>
Content-Type: multipart/alternative;
	boundary="j6ErgrnnWYg9=_?:"
X-Authenticated_sender: 

This is a multi-part message in MIME format.

--j6ErgrnnWYg9=_?:
Content-Type: text/plain;
	charset="us-ascii"
Content-Transfer-Encoding: 7bit

To view this email as a web page, go to the link below, or copy and paste it into your browser's address window.
http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad20cd60c5bad261dea0b7fb6f3df39987b49b717938bec7c34ce10282e4cba04a7ASCO Advertisement

 

http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad28ec9df49b7fa586c63acafcc708b7f28aed238227be3271d0560ef100eb4e579 

http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad209949dada2cf52d90718ec685a295a8796f77789711f8993ab9255ed3e39947b 
2015 ASCO Annual Meeting Unites More than 37,000 in Fight Against Cancer 

http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad209949dada2cf52d90718ec685a295a8796f77789711f8993ab9255ed3e39947b 

 
The 2015 ASCO Annual Meeting examined value and cost of cancer care at an event that saw a record total of nearly 6,000 abstracts submitted for review.


http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad209949dada2cf52d90718ec685a295a8796f77789711f8993ab9255ed3e39947b 
Read the Full Story » 

 

ASCO's 2015 Plenary Sessions

http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2916b7a6bc025d5b6589a616a97c6dd1e5ffc73461190515f928446d3325757e2 
Abstract LBA1: Nivolumab, Ipilimumab Combination Effective in Advanced Melanoma; Cost Questions Raised  

http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2f5a4402b04b9947d5dba971a708b0c3c6f438bd823cfd142ff59cc6c64bd65a5 

Abstract LBA2: Changes in Pediatric Cancer Treatments Yield Reduced Late Mortality

http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2fb64f1f6a7390cb6a139a550b0881f2f25f3ebc551870e55647473ce83ff37b2 

Abstract LBA3: Elective Neck Dissection Improves Survival in Early Oral Cancers 

http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2e5eb3ad2860e5f1d295484668da76452f65c8753d0ea4046f015420b01dda96d 

Abstract LBA4: In Brain Metastases, Adding WBRT to SRS Improves Local Control but Not Survival

 

http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad227fa0337625bed045c39d039db2758900131b73ba020d71549b6628f3b794a38 
 
http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad227fa0337625bed045c39d039db2758900131b73ba020d71549b6628f3b794a38 
Single-Agent Daratumumab Active in Heavily Pretreated, Refractory Multiple Myeloma 

The CD38-targeted monoclonal antibody daratumumab showed promising single-agent activity in patients with heavily pretreated relapsed and refractory multiple myeloma (Abstract LBA8512), according to data presented by Dr. Sagar Lonial (pictured). 


http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad227fa0337625bed045c39d039db2758900131b73ba020d71549b6628f3b794a38 
Read the Full Story » 

 

http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2aa5cad013b38251233f8c6053e9c7cad0f723e80c555e82ac00582ef69cfaca3 
Phase III Trial Finds PFS Benefit with Trabectedin in Soft Tissue Sarcoma 

http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2aa5cad013b38251233f8c6053e9c7cad0f723e80c555e82ac00582ef69cfaca3 
 
In a randomized, open-label phase III trial, trabectedin failed to show OS improvement over dacarbazine in patients with advanced liposarcoma or leiomyosarcoma, but it did show a significant improvement in progression-free survival (Abstract 10503), according to results presented by Dr. George D. Demetri (pictured).


http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2aa5cad013b38251233f8c6053e9c7cad0f723e80c555e82ac00582ef69cfaca3 
Read the Full Story » 

 

http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2a58d9b8ee4664c0a1a18aaefb563dc88837dcfa8a6e66d7018fc21e28571eee1 
Moving Cancer Survivorship Care Forward 
During the Education Session "Moving Survivorship Forward: Lessons from Quality Care Measures," quality care in cancer survivorship was discussed along with some metrics that indicated we have a long way to go in improving quality care for cancer survivors.

http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2a58d9b8ee4664c0a1a18aaefb563dc88837dcfa8a6e66d7018fc21e28571eee1 
Read the Full Story >> 

 

http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2a79e2368aafd93bfc3ff304bb379b0e4352a05dd2485fe214966c07b8fbec773 
ASCO, NCI Announce Plans for Precision Medicine Trials  

http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2a79e2368aafd93bfc3ff304bb379b0e4352a05dd2485fe214966c07b8fbec773 
 
At a press briefing on Monday, June 1, plans were announced for ASCO's Targeted Agent and Profiling Utilization Registry (TAPUR) study (presented by Dr. Richard L. Schilsky [pictured]) and the NCI-MATCH: Molecular Analysis for Therapy Choice trial (EAY131). 


http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2a79e2368aafd93bfc3ff304bb379b0e4352a05dd2485fe214966c07b8fbec773 
Read the Full Story >> 

 

http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad23c9d4a5a56c87afc4d9d114f2cfababcac87c0be3dc99f6210e9b1e422a6d074 

Cost of Cancer Drugs Should Be Part of Treatment Decisions
 

http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad23c9d4a5a56c87afc4d9d114f2cfababcac87c0be3dc99f6210e9b1e422a6d074 
 
The Health Services Research and Quality of Care Oral Abstract Session focused on how cost does not always reflect drug value, efforts to consider cost as part of treatment decisions, and methods to set new drug prices based on value. Dr. Peter B. Bach (pictured) asked, "Why treat prices as immutable? Would we really pay an infinite amount for a microscopic benefit?" 


http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad23c9d4a5a56c87afc4d9d114f2cfababcac87c0be3dc99f6210e9b1e422a6d074 
Read the Full Story >> 

 

Experiences with the Community Oncology Medical Home (COME HOME) Grant

	- 
http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad29c3e193a4c4da08c8191159080efcd0b7cf6916008901166efb964c605e8e874 

COME HOME Program Changes the Face of Cancer Care Delivery at Dayton Physicians Network
 

	- 
http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad22d4363bc50400e609cf8bbc37eab2958e811b3c695c93a52f92e8069a8f5ecca 

COME HOME Project: The Center for Cancer and Blood Disorders Experience  
	- 
http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2c898358d9f71022191d07ab5694d645de43869ccc5b3730fe8280eba806c7453 

COME HOME Project Seeks to Enhance Patient Care, Reduce Costs, and Improve Outcomes  

 

http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2063304d89fa6727626b9c1d8c79d456b80b91177796b59a47560b0ac3b04cf54 
ASCO Daily News Home
http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2266a37f5f5a64dd706a69cf29b1cf964826f788789b1a4c9c6165eef2cc31166 
 | 
http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad281189d6e192443501e43bde3b9205c3dd3e6134c04c6a5f124a98c5f068da468 
Session Coverage  | 
http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad29d077dc99fa33db90e0a53605fff961fe685c664ea8ae8d64440d31029b80ede 
Expert Editorials 

http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2c7952195ba76e7d795fa9c64e7b6947c7e6c8d2305a4508f869d7b5a7cd82258 
Grants and Awards  | 
http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad289fe9ee7ae38a7ca1c075fedcd7e1a1009b6fdb1fd57153097d69604cd9b52f7 
am.asco.org 

Connect with us:
http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad20010a8faf70a6c6f2ab8ef7bf6342474ccbeff41bbde20b8b75e094f56b1e7c1 

http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad21db8ea28c93c9ddd3b94942e2aeb2cebeda2cd03c3e057b780f6d3006fd64950 

http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad234af8dcedb427de857533f72ff2b2023f42b805771b07b652a7628a9ce2c5122 

http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad25899b632b0cfc1894d4ee8acf69708c7f4705dfc80e1e104d64e7bc6930dfdcf 
Forward to a Colleague 
http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad25899b632b0cfc1894d4ee8acf69708c7f4705dfc80e1e104d64e7bc6930dfdcf 

 
http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2155f7db5c781d0d4585af75568267ca189d56d8f617da114b3e63324cd8639fd 


Advertisement








You are receiving this email because you have an existing relationship
with ASCO.  Visit your personalized 
http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2efaf84ff3fbdd2ab92921a96d1faf608ccd82aa474c1590e3b8c8c5581cb39d753a259e9889480c3 
Preference Center  to unsubscribe or to select
your preferences for receiving ASCO promotional email.  Please do
not reply to this email.  

This email was sent by: American Society of Clinical Oncology

2318 Mill Road, Suite 800 Alexandria, VA,
22314, USA



--j6ErgrnnWYg9=_?:
Content-Type: text/html;
	charset="us-ascii"
Content-Transfer-Encoding: 7bit

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<div style="display:block;width:100%;text-align:center;font-family: Verdana, sans-serif;font-size:10px;color:#444444;padding:8px 0;margin:auto;">
	To view this email as a web page, go   <a href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad23188595ef7aac737fe7c0d04ab3420494a08cca70abcae428181f74cf0aafd42" > here</a>.
</div><!DOCTYPE html>
<html lang="en">

<head>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
    <title>ASCO</title>

    <style>
        
        body {margin:0; padding:0; -webkit-text-size-adjust:none; -ms-text-size-adjust:none;} img{line-height:100%; outline:none; text-decoration:none; -ms-interpolation-mode: bicubic;} a img{border: none;} #backgroundTable {margin:0; padding:0; width:100% !important; } a, a:link{color:#318786; text-decoration: none;} table td {border-collapse:collapse;} span {color: inherit; border-bottom: none;} span:hover { background-color: transparent; }

    </style>
</head><body style="background: #d8d8d8;font-family:Arial, Helvetica, sans-serif; font-size:1em;">


    <table id="backgroundTable" width="100%" cellspacing="0" cellpadding="0" border="0" style="background:#d8d8d8;">
        <tr>
            <td class="body" align="center" valign="top" style="background:#d8d8d8;" width="100%">
                <table cellpadding="0" cellspacing="0">
                    <tr>
                        <td class="banner" width="826" align="center" style="background: #d8d8d8; padding-top: 16px;">
                            <table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><div align="center"><img vspace="0" hspace="0" border="0" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/GNE_banner_728x90_mm_c2_v3.jpg" title="GNE_banner_728x90_mm_c2_v3" alt="GNE_banner_728x90_mm_c2_v3" /></div><div align="center">&nbsp;</div><div align="center">Advertisement</div></td></tr></table></td></tr></table>&nbsp;
                        </td>
                    </tr>
                    <tr>
                       
                    </tr>
                    <tr>
                        <td class="main" width="826" align="center">
                            <table cellpadding="0" cellspacing="0">
	<tr>
        <td class="header" width="826" align="left">
            <table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><a   title="AM2015 Daily News" href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2f219da7601a6fddcd3331e501b487bd544a090d6aa735dedf4d2eda801abbb21"><img width="826" height="115" border="0" style="width: 826px; height: 115px; border-color: #000000; margin: 0px;" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/Wrap+Up+eDigest.png" title="AM15daily-banner-826x115-eDigest" alt="AM15daily-banner-826x115-eDigest" thid="37e5816e-7240-4baf-ae3a-6055065e8173" /></a></td></tr></table></td></tr>
</table>
        </td>
    </tr>
    <tr>
    	<td class="subheader" width="826" align="left">
    		
    	</td>
    </tr>
    <tr>
    	<td width="826" style="background: #d8d8d8;">
    		<table cellpadding="0" cellspacing="0">
    			<tr>
    				<td style="padding: 16px;">
    					<table cellpadding="0" cellspacing="0">
    						<tr>
    							<td width="618" valign="top">
    								<table cellpadding="0" cellspacing="0">
    									<tr>
    										<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellpadding="0" cellspacing="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="left" style="background: #ffffff;">
			<table cellpadding="0" cellspacing="0">
				<tbody>
					<tr>
						<td style="padding: 20px 24px;">
						<table cellpadding="0" cellspacing="0">
							<tbody>
								<tr>
									<td align="left" style="font-family: arial, sans-serif; font-size: 18px; font-weight: bold; color: #318786; padding-bottom: 12px;">
									<a href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad229716f810be1754832585a788823987c5c7bcac20fdf69d40eb387d1dcf1d2f0" style="text-decoration: none; color: #318786;" title="2015 ASCO Annual Meeting Unites More than 37,000 in Fight Against Cancer"  >2015 ASCO Annual Meeting Unites More than 37,000 in Fight Against Cancer</a>
									</td>
								</tr>
								<tr>
									<td width="570" align="left">
									<table cellpadding="0" cellspacing="0">
										<tbody>
											<tr>
												<td valign="top">
												<table cellpadding="0" cellspacing="0">
													<tbody>
														<tr>
															<td width="284">
															<a href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad229716f810be1754832585a788823987c5c7bcac20fdf69d40eb387d1dcf1d2f0" title="2015 ASCO Annual Meeting Unites More than 37,000 in Fight Against Cancer"  ><img src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/Digest.jpg" alt="Digest" style="display: block; border: 0px; width: 284px; height: 148px; margin: 0px;" title="Digest" thid="492b2c90-e7d4-4ad0-874b-4f3c16211d2a" width="284" height="148" /></a>
															</td>
														</tr>
														<tr>
															<td width="284" style="font-size: 12px; font-family: Arial, sans-serif; line-height: 18px !important;"><br />
															</td>
														</tr>
													</tbody>
												</table>
												</td>
												<td width="24" style="font-size: 1px;">&nbsp;</td>
												<td width="262" align="left" valign="top">
												<table cellpadding="0" cellspacing="0">
													<tbody>
														<tr>
															<td align="left" style="font-family: arial, sans-serif; font-size: 14px; color: #747474; padding-bottom: 16px; line-height: 18px !important;">
															The 2015 ASCO Annual Meeting examined value and cost of cancer care at an event that saw a record total of nearly 6,000 abstracts submitted for review.
															</td>
														</tr>
														<tr>
															<td align="left" style="font-family: arial, sans-serif; font-size: 18px; font-weight: bold; color: #318786;">
															<a href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad229716f810be1754832585a788823987c5c7bcac20fdf69d40eb387d1dcf1d2f0" style="text-decoration: none; color: #318786;" title="2015 ASCO Annual Meeting Unites More than 37,000 in Fight Against Cancer"  >Read the Full Story &#187;</a>
															</td>
														</tr>
													</tbody>
												</table>
												</td>
											</tr>
										</tbody>
									</table>
									</td>
								</tr>
							</tbody>
						</table>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
		<tr>
			<td width="618" height="16" style="font-size: 1px;">&nbsp;</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
    									</tr>
    									<tr>
    										<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellpadding="0" cellspacing="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="left" style="background: #ffffff;">
			<table cellpadding="0" cellspacing="0">
				<tbody>
					<tr>
						<td style="padding: 20px 24px;">
						<table cellpadding="0" cellspacing="0">
							<tbody>
								<tr>
									<td align="left" style="font-family: arial, sans-serif; font-size: 18px; font-weight: bold; color: #318786; padding-bottom: 12px;">ASCO's 2015 Plenary Sessions</td>
								</tr>
								<tr>
									<td align="left" style="font-family: arial, sans-serif; font-size: 14px; color: #747474; padding-bottom: 16px; line-height: 18px !important;"><a   href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad271cac597bc435b36f150bb17d8c52585ff8166ee775163bba8b8f9eb16e06db8" title=" ASCO Plenary Briefing: Nivolumab, Ipilimumab Combination Effective in Advanced Melanoma" style="color: #318786; text-decoration: none;">Abstract LBA1: Nivolumab, Ipilimumab Combination Effective in Advanced Melanoma; Cost Questions Raised&nbsp;</a><br /><a   href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad280ddf681792068d1e320ccf82124e63be9416338f20444504236fa8644301d7d" title=" ASCO Plenary Briefing: Changes in Pediatric Cancer Treatments Yield Reduced Late Mortality" style="color: #318786; text-decoration: none;">
<br />Abstract LBA2: Changes in Pediatric Cancer Treatments Yield Reduced Late Mortality</a><br /><a   href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad283a1790ae4b23511cb1173791e654ccf22440092776dddf98372dc2b9a1ce4c2" title=" ASCO Plenary Briefing: Elective Neck Dissection Improves Survival in Early Oral Cancers" style="color: #318786; text-decoration: none;"><br />Abstract LBA3: Elective Neck Dissection Improves Survival in Early Oral Cancers&nbsp;</a><br /><a   href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2fc735574092595ab3f7045c909c91b57b7786e63d7548d07b6d48babadc69065" title=" ASCO Plenary Briefing: In Brain Metastases, Adding WBRT to SRS Improves Local Control but Not Survival" style="color: #318786; text-decoration: none;">
<br />Abstract LBA4: In Brain Metastases, Adding WBRT to SRS Improves Local Control but Not Survival</a></td>
								</tr>
								<tr>
									<td align="left" style="font-family: arial, sans-serif; font-size: 18px; font-weight: bold; color: #318786;"><br /></td>
								</tr>
							</tbody>
						</table>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
		<tr>
			<td width="618" height="16" style="font-size: 1px;">&nbsp;</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
    									</tr>
    									<tr>
    										<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellpadding="0" cellspacing="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="left" style="background: #ffffff;">
			<table cellpadding="0" cellspacing="0">
				<tbody>
					<tr>
						<td style="padding: 20px 24px;">
						<table cellpadding="0" cellspacing="0">
							<tbody>
								<tr>
									<td width="168" valign="top">
									<a href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad289b7bf49a03907954f1da7b0b4b4f2b2a27a8c24d71ed0683b9dcbbec80faa09" title="Single-Agent Daratumumab Active in Heavily Pretreated, Refractory Multiple Myeloma"  ><img src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/Lonial.jpg" alt="Lonial" style="display: block; border: 0px; width: 168px; height: 174px; margin: 0px;" title="Lonial" thid="0fe8a98a-a7d2-402d-b07f-237341ca65a0" width="168" height="174" /></a>
									</td>
									<td width="24" style="font-size: 1px;">&nbsp;</td>
									<td width="378" align="left" valign="top">
									<table cellpadding="0" cellspacing="0">
										<tbody>
											<tr>
												<td align="left" style="font-family: arial, sans-serif; font-size: 18px; font-weight: bold; color: #318786; padding-bottom: 12px;">
												<a href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad289b7bf49a03907954f1da7b0b4b4f2b2a27a8c24d71ed0683b9dcbbec80faa09" style="text-decoration: none; color: #318786;" title="Single-Agent Daratumumab Active in Heavily Pretreated, Refractory Multiple Myeloma"  >Single-Agent Daratumumab Active in Heavily Pretreated, Refractory Multiple Myeloma</a>
												</td>
											</tr>
											<tr>
												<td align="left" style="font-family: arial, sans-serif; font-size: 14px; color: #747474; padding-bottom: 16px; line-height: 18px !important;">
												The CD38-targeted monoclonal antibody daratumumab showed promising single-agent activity in patients with heavily pretreated relapsed and refractory multiple myeloma (Abstract LBA8512), according to data presented by Dr. Sagar Lonial (pictured). 
												</td>
											</tr>
											<tr>
												<td align="left" style="font-family: arial, sans-serif; font-size: 18px; font-weight: bold; color: #318786;">
												<a href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad289b7bf49a03907954f1da7b0b4b4f2b2a27a8c24d71ed0683b9dcbbec80faa09" style="text-decoration: none; color: #318786;" title="Single-Agent Daratumumab Active in Heavily Pretreated, Refractory Multiple Myeloma"  >Read the Full Story &#187;</a>
												</td>
											</tr>
										</tbody>
									</table>
									</td>
								</tr>
							</tbody>
						</table>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
		<tr>
			<td width="618" height="16" style="font-size: 1px;">&nbsp;</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
    									</tr>
    									<tr>
    										<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellpadding="0" cellspacing="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="left" style="background: #ffffff;">
			<table cellpadding="0" cellspacing="0">
				<tbody>
					<tr>
						<td style="padding: 20px 24px;">
						<table cellpadding="0" cellspacing="0">
							<tbody>
								<tr>
									<td align="left" style="font-family: arial, sans-serif; font-size: 18px; font-weight: bold; color: #318786; padding-bottom: 12px;">
									<a href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2e8c5f052883634a110963dded9c34eb29beda8606db2bbe57af6f0b3d8af0c22" style="text-decoration: none; color: #318786;" title="Phase III Trial Finds PFS Benefit with Trabectedin in Soft Tissue Sarcoma"  >Phase III Trial Finds PFS Benefit with Trabectedin in Soft Tissue Sarcoma</a>
									</td>
								</tr>
								<tr>
									<td width="570" align="left">
									<table cellpadding="0" cellspacing="0">
										<tbody>
											<tr>
												<td width="284" valign="top">
												<a href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2e8c5f052883634a110963dded9c34eb29beda8606db2bbe57af6f0b3d8af0c22" title="Phase III Trial Finds PFS Benefit with Trabectedin in Soft Tissue Sarcoma"  ><img src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/Photo.jpg" alt="Photo" style="display: block; border: 0px; width: 284px; height: 148px; margin: 0px;" title="Photo" thid="ecef2b28-5da6-465d-9a3d-8f4b16acc258" width="284" height="148" /></a>
												</td>
												<td width="24" style="font-size: 1px;">&nbsp;</td>
												<td width="262" align="left" valign="top">
												<table cellpadding="0" cellspacing="0">
													<tbody>
														<tr>
															<td align="left" style="font-family: arial, sans-serif; font-size: 14px; color: #747474; padding-bottom: 16px; line-height: 18px !important;">
															In a randomized, open-label phase III trial, trabectedin failed to show OS improvement over dacarbazine in patients with advanced liposarcoma or leiomyosarcoma, but it did show a significant improvement in progression-free survival (Abstract 10503), according to results presented by Dr. George D. Demetri (pictured).
															</td>
														</tr>
														<tr>
															<td align="left" style="font-family: arial, sans-serif; font-size: 18px; font-weight: bold; color: #318786;">
															<a href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2e8c5f052883634a110963dded9c34eb29beda8606db2bbe57af6f0b3d8af0c22" style="text-decoration: none; color: #318786;" title="Phase III Trial Finds PFS Benefit with Trabectedin in Soft Tissue Sarcoma"  >Read the Full Story &#187;</a>
															</td>
														</tr>
													</tbody>
												</table>
												</td>
											</tr>
										</tbody>
									</table>
									</td>
								</tr>
							</tbody>
						</table>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
		<tr>
			<td width="618" height="16" style="font-size: 1px;">&nbsp;</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
    									</tr>
    									<tr>
    										<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellpadding="0" cellspacing="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="left" style="background: #ffffff;">
			<table cellpadding="0" cellspacing="0">
				<tbody>
					<tr>
						<td style="padding: 20px 24px;">
						<table cellpadding="0" cellspacing="0">
							<tbody>
								<tr>
									<td align="left" style="font-family: arial, sans-serif; font-size: 18px; font-weight: bold; color: #318786; padding-bottom: 12px;"><a href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2bae26175db77cdc06de8dd3ceaee9e1b38eed9d1216ac28d60794ee8f90366d8" title="Moving Cancer Survivorship Care Forward"   style="color: #318786; text-decoration: none;">Moving Cancer Survivorship Care Forward</a></td>
								</tr>
								<tr>
									<td align="left" style="font-family: arial, sans-serif; font-size: 14px; color: #747474; padding-bottom: 16px; line-height: 18px !important;">During the Education Session "Moving Survivorship Forward: Lessons from Quality Care Measures," quality care in cancer survivorship was discussed along with some metrics that indicated we have a long way to go in improving quality care for cancer survivors.</td>
								</tr>
								<tr>
									<td align="left" style="font-family: arial, sans-serif; font-size: 18px; font-weight: bold; color: #318786;"><a href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2bae26175db77cdc06de8dd3ceaee9e1b38eed9d1216ac28d60794ee8f90366d8" title="Moving Cancer Survivorship Care Forward"   style="color: #318786; text-decoration: none;">Read the Full Story &raquo;</a></td>
								</tr>
							</tbody>
						</table>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
		<tr>
			<td width="618" height="16" style="font-size: 1px;">&nbsp;</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
    									</tr>
    									<tr>
    										<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellspacing="0" cellpadding="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="left" style="background: none 0% 0% repeat scroll #ffffff;">
			<table cellspacing="0" cellpadding="0">
				<tbody>
					<tr>
						<td style="padding: 20px 24px;">
						<table cellspacing="0" cellpadding="0">
							<tbody>
								<tr>
									<td align="left" style="font-family: arial, sans-serif; font-size: 18px; font-weight: bold; color: #318786; padding-bottom: 12px;">
									<a   title="ASCO, NCI Announce Plans for Precision Medicine Trials" style="text-decoration: none; color: #318786;" href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2f06a8976b17a5384d58bc046cbb1df73b5497b7814749dc78209b65893ee2bef">ASCO, NCI Announce Plans for Precision Medicine Trials </a>
									</td>
								</tr>
								<tr>
									<td width="570" align="left">
									<table cellspacing="0" cellpadding="0">
										<tbody>
											<tr>
												<td width="284" valign="top">
												<a   title="ASCO, NCI Announce Plans for Precision Medicine Trials" href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2f06a8976b17a5384d58bc046cbb1df73b5497b7814749dc78209b65893ee2bef"><img width="284" height="148" thid="290751a8-7c99-4e0a-9fef-6a10217a90e0" title="Schilsky_168x144" style="display: block; border: 0px none; width: 284px; height: 148px; margin: 0px;" alt="Schilsky_168x144" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/Schilsky_284x188.jpg" /></a>
												</td>
												<td width="24" style="font-size: 1px;">&nbsp;</td>
												<td width="262" valign="top" align="left">
												<table cellspacing="0" cellpadding="0">
													<tbody>
														<tr>
															<td align="left" style="font-family: arial, sans-serif; font-size: 14px; color: #747474; padding-bottom: 16px; line-height: 18px !important;">
															At a press briefing on Monday, June 1, plans were announced for ASCO's Targeted Agent and Profiling Utilization Registry (TAPUR) study (presented by Dr. Richard L. Schilsky [pictured]) and the NCI-MATCH: Molecular Analysis for Therapy Choice trial (EAY131). 
															</td>
														</tr>
														<tr>
															<td align="left" style="font-family: arial, sans-serif; font-size: 18px; font-weight: bold; color: #318786;">
															<a   title="ASCO, NCI Announce Plans for Precision Medicine Trials" style="text-decoration: none; color: #318786;" href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2f06a8976b17a5384d58bc046cbb1df73b5497b7814749dc78209b65893ee2bef">Read the Full Story &raquo;</a>
															</td>
														</tr>
													</tbody>
												</table>
												</td>
											</tr>
										</tbody>
									</table>
									</td>
								</tr>
							</tbody>
						</table>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
		<tr>
			<td width="618" height="16" style="font-size: 1px;">&nbsp;</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
    									</tr>
    									<tr>
    										<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellspacing="0" cellpadding="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="left" style="background: none 0% 0% repeat scroll #ffffff;">
			<table cellspacing="0" cellpadding="0">
				<tbody>
					<tr>
						<td style="padding: 20px 24px;">
						<table cellspacing="0" cellpadding="0">
							<tbody>
								<tr>
									<td align="left" style="font-family: arial, sans-serif; font-size: 18px; font-weight: bold; color: #318786; padding-bottom: 12px;">
									<a href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2ab776a9a687f0dd66f41070edacd10ea0fd14710edc62c6f4daa6414f78d56b5" style="text-decoration: none; color: #318786;" title=" Cost of Cancer Drugs Should Be Part of Treatment Decisions"  >
									Cost of Cancer Drugs Should Be Part of Treatment Decisions
									</a>
									</td>
								</tr>
								<tr>
									<td width="570" align="left">
									<table cellspacing="0" cellpadding="0">
										<tbody>
											<tr>
												<td width="284" valign="top">
												<a href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2ab776a9a687f0dd66f41070edacd10ea0fd14710edc62c6f4daa6414f78d56b5" title=" Cost of Cancer Drugs Should Be Part of Treatment Decisions"  ><img width="284" height="148" thid="8b2dea10-f85a-43d3-b049-3ddd1d78a304" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/Peter_Bach.jpg" alt="Peter_Bach" style="display: block; border: 0px none; width: 284px; height: 148px; margin: 0px;" title="Peter_Bach" /></a>
												</td>
												<td width="24" style="font-size: 1px;">&nbsp;</td>
												<td width="265" valign="top" align="left">
												<table cellspacing="0" cellpadding="0">
													<tbody>
														<tr>
															<td align="left" style="font-family: arial, sans-serif; font-size: 14px; color: #747474; padding-bottom: 16px; line-height: 18px !important;">
															The Health Services Research and Quality of Care Oral Abstract Session focused on how cost does not always reflect drug value, efforts to consider cost as part of treatment decisions, and methods to set new drug prices based on value. Dr. Peter B. Bach (pictured) asked, &quot;Why treat prices as immutable? Would we really pay an infinite amount for a microscopic benefit?&quot; 
															</td>
														</tr>
														<tr>
															<td align="left" style="font-family: arial, sans-serif; font-size: 18px; font-weight: bold; color: #318786;">
															<a href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2ab776a9a687f0dd66f41070edacd10ea0fd14710edc62c6f4daa6414f78d56b5" style="text-decoration: none; color: #318786;" title=" Cost of Cancer Drugs Should Be Part of Treatment Decisions"  >Read the Full Story &raquo;</a>
															</td>
														</tr>
													</tbody>
												</table>
												</td>
											</tr>
										</tbody>
									</table>
									</td>
								</tr>
							</tbody>
						</table>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
		<tr>
			<td width="618" height="16" style="font-size: 1px;">&nbsp;</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
    									</tr>
									    <tr>
									    	<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellspacing="0" cellpadding="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="left" style="background: none 0% 0% repeat scroll #ffffff;">
			<table cellspacing="0" cellpadding="0">
				<tbody>
					<tr>
						<td style="padding: 20px 24px;">
						<table cellspacing="0" cellpadding="0">
							<tbody>
								<tr>
									<td align="left" style="font-family: arial, sans-serif; font-size: 18px; font-weight: bold; color: #318786; padding-bottom: 12px;">Experiences with the Community Oncology Medical Home (COME HOME) Grant</td>
								</tr>
							</tbody>
						</table>
						<table cellspacing="0" cellpadding="0">
							<tbody>
								<tr>
									<td align="left" style="font-family: arial, sans-serif; font-size: 14px; color: #747474; padding-bottom: 16px; line-height: 18px !important;">
									<ul>
										<li><a href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2ef5b9c3812776c3fe3bc7edc9448d39f28c85364b8d740742c249b2cae408e51" title="COME HOME Program Changes the Face of Cancer Care Delivery at Dayton Physicians Network" style="color: #318786; text-decoration: none;"  >
										COME HOME Program Changes the Face of Cancer Care Delivery at Dayton Physicians Network
										</a><br />
										</li>
										<li><a href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad259f6ae1ac04d27ccbdc7aeebee8fce7d14402e8013618d2c6158011d6d90c3f7" title="COME HOME Project: The Center for Cancer and Blood Disorders Experience" style="color: #318786; text-decoration: none;"  >
										COME HOME Project: The Center for Cancer and Blood Disorders Experience&nbsp;</a></li>
										<li><a href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad235688c82aa7881d6175b471502bd3a90f0461140989289ae0d46a2ba400377f6" title="COME HOME Project Seeks to Enhance Patient Care, Reduce Costs, and Improve Outcomes" style="color: #318786; text-decoration: none;"  >
										COME HOME Project Seeks to Enhance Patient Care, Reduce Costs, and Improve Outcomes&nbsp;</a></li>
									</ul>
									</td>
								</tr>
							</tbody>
						</table>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
		<tr>
			<td width="618" height="16" style="font-size: 1px;">&nbsp;</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
									    </tr>
									    <tr>
									    	<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellspacing="0" cellpadding="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="center" style="border-top: 1px solid #ffffff; border-bottom: 2px solid #ffffff; padding: 12px 0px; background: #d2e8e2 none repeat scroll 0% 0%;">
			<table cellspacing="0" cellpadding="0">
				<tbody>
					<tr>
						<td align="center" style="font-family: arial,sans-serif; font-size: 16px; font-weight: bold; color: #6a6a6a; line-height: 30px ! important;">
						<a title="https://am.asco.org/daily-news" style="text-decoration: none; color: #318786;" href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad262e2331f5943bcbf454e881978f035e88656fa8a3329a8b97ea8f5f940af5d82"  ><i>ASCO Daily News</i> Home</a><a   title="ASCO Daily News Home" href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad26459fd48f1f06c1324a7911e2fa3e94879a5cf2abcb8cae2611c425f68d4bf906e10091182a52eed"></a> | <a   title="Session coverage" style="text-decoration: none; color: #318786;" href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2546b5e119554a875a0eb0f4514806b9f8662ae2da7a88d359bf9eedbb100254cc256770652fae6c2">Session Coverage</a> | <a   title="Expert editorials" style="text-decoration: none; color: #318786;" href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2af1ddbd522d4f69b6537b8e791b351302d19f3a096830ccdab47305380569d3fe9a72561ece4e379">Expert Editorials</a>
						</td>
					</tr>
					<tr>
						<td align="center" style="font-family: arial,sans-serif; font-size: 16px; font-weight: bold; color: #6a6a6a; line-height: 30px ! important;">
						<a   title="Grants and Awards" style="text-decoration: none; color: #318786;" href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad258a8eeb41084975c6273c0322a4d4c317348b2e9282eb3b8c0a6d6142496118b9ee67467ddb5e210">Grants and Awards</a> | <a   title="am.asco.org" style="text-decoration: none; color: #318786;" href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2315f5c896d774ba64a5bb81dd61f426786a0409d630309d428cbcad06aa343715d9412cdb22c22ed">am.asco.org</a>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
									    </tr>
									    <tr>
									    	<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellpadding="0" cellspacing="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="center" style="padding: 12px 0px; background: #efefef;">
			<table cellpadding="0" cellspacing="0">
				<tbody>
					<tr>
						<td style="font-family: arial, sans-serif; font-size: 16px; color: #575757; padding-right: 10px;">Connect with us:</td>
						<td style="padding-right: 10px;"><a href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2c1d2bf1999fa2945992abff91a3f2ab5ece41f528642245080c1c53e0f991acd71bd359154a6f040" title="Twitter"  ><img src="http://image.broadcastemail.asco.org/lib/fe66157077670d7f7712/m/1/eDigest_11.jpg" style="display: block; border: 0px; width: 32px; height: 32px; margin: 0px;" width="32" height="32" /></a></td>
						<td style="padding-right: 10px;"><a href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad24f21d491419ac8813abc16b289acd5f348f4eee0b04548e158cce2c406fd90633f4ac33db358ca9b" title="Facebook"  ><img src="http://image.broadcastemail.asco.org/lib/fe66157077670d7f7712/m/1/eDigest_13.jpg" style="display: block; border: 0px; width: 32px; height: 32px; margin: 0px;" width="32" height="32" /></a></td>
						<td style="padding-right: 10px;"><a href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad200894f00c07e6a0bdd2a2f6870b94123c3730ec163b8d33e5751f8265430da625b61571f91a04e9f" title="Linkedin"  ><img src="http://image.broadcastemail.asco.org/lib/fe66157077670d7f7712/m/1/eDigest_15.jpg" style="display: block; border: 0px; width: 32px; height: 32px; margin: 0px;" width="32" height="32" /></a></td>
						<td style="padding-right: 20px;"></td>
						<td style="font-family: arial, sans-serif; font-size: 16px; color: #575757; padding-right: 10px;">
						<a href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad27c0283d4c5ec41dbc8d48160ed899dbb5c47d7d84b29f3dfbee4f572b074a389" style="text-decoration: none; color: #318786;">Forward to a Colleague</a>
						</td>
						<td><a href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad27c0283d4c5ec41dbc8d48160ed899dbb5c47d7d84b29f3dfbee4f572b074a389"><img src="http://image.broadcastemail.asco.org/lib/fe66157077670d7f7712/m/1/eDigest_19.jpg" alt="Email" style="display: block; border: 0px;" /></a></td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
									    </tr>
    								</table>
    							</td>
    							<td width="16" style="font-size: 1px; min-width: 16px;">&nbsp;</td>
    							<td width="160" valign="top">
    								<table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><div align="center">
<a href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad2200d3e416f5f06dcac8531a099ff097a64f2b03e1c545bcd3dcdf0d77ef5486a" title="ASCO Connection"  ><img width="160" height="600" border="0" alt="AC-web-ad-160x600_2015-05-26" title="AC-web-ad-160x600_2015-05-26" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/AC-web-ad-160x600_2015-05-26.png" style="width: 160px; height: 600px; border-color: #000000; margin: 0px;" /></a><br />
Advertisement<br />
</div></td></tr></table></td></tr></table>
    							</td>
    						</tr>
    					</table>
    				</td>
    			</tr>
    		</table>
    	</td>
    </tr>
    <tr>
    	<td class="disclaimer" width="826" align="center">
    		
    	</td>
    </tr>
</table>
                        </td>
                    </tr>
                    <tr>
                      
                                            </tr>
                                        </table>
                                    </td>
                                </tr>
                            </table>
                        </td>
                    </tr>
                </table>
            </td>
        </tr>
    </table>

    <!-- Exact Target tracking code -->
    <img src="http://click.broadcastemail.asco.org/open.aspx?ffcb10-fe5d177677640d78741c-fdc61574706c037c7112727664-fe6015707d670579731c-fe6415787165027c7710-fe271d7877640475761579-ff60107472" width="1" height="1">

</body>
 <!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<title></title>
</head><body style="background: #d8d8d8;font-family:Arial, Helvetica, sans-serif; font-size:1em;">
<body>


<div width="850" style="margin-left: auto; margin-right: auto; width: 850px; text-align: left;">

You are receiving this email because you have an existing relationship
with ASCO.&nbsp; Visit your personalized <a
href="http://click.broadcastemail.asco.org/?qs=605dd622cfba9ad29977d1902e308cadaa66a1ed5d1eba24d00fe7cb44f6444759fa3779a64695e463a17e96071f1879"
target="_blank">Preference Center</a> to unsubscribe or to select
your preferences for receiving ASCO promotional email.&nbsp; Please do
not reply to this email.&nbsp; <br>
This email was sent by: American Society of Clinical Oncology<br>
2318 Mill Road, Suite 800 Alexandria, VA,
22314, USA<br></div>
</body>
</body>
</html>

--j6ErgrnnWYg9=_?:--

